Overview

Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475

Status:
Unknown status

Trial end date:
2018-06-01

Target enrollment:

Participant gender:

Summary

It is known that after application of MK-3475 activated PD -1 negatively regulates the activation of T cells through suppression of the path of PI3K / Akt. This study will identify the effectiveness of oral inhibitors of PI3K / Akt pathway in comparison with MK-3475 (pembrolizumab).

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Medical Research Council

Collaborators:

Aarhus University Hospital
Department of Experimental Clinical Oncology, Aarhus University Hospital
ECCO - the European CanCer Organisation
Merck Sharp & Dohme Corp.
NCRI Clinical Studies Groups

Treatments:

Dactolisib
Pembrolizumab